RU2720160C2 - Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима - Google Patents
Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима Download PDFInfo
- Publication number
- RU2720160C2 RU2720160C2 RU2017146070A RU2017146070A RU2720160C2 RU 2720160 C2 RU2720160 C2 RU 2720160C2 RU 2017146070 A RU2017146070 A RU 2017146070A RU 2017146070 A RU2017146070 A RU 2017146070A RU 2720160 C2 RU2720160 C2 RU 2720160C2
- Authority
- RU
- Russia
- Prior art keywords
- holder
- clamp
- clip
- cover
- needle
- Prior art date
Links
- 239000007924 injection Substances 0.000 title claims abstract description 59
- 238000002347 injection Methods 0.000 title claims abstract description 59
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 238000005452 bending Methods 0.000 claims abstract description 15
- 238000005520 cutting process Methods 0.000 claims abstract description 7
- 238000009434 installation Methods 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 2
- 230000000717 retained effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 28
- 229940079593 drug Drugs 0.000 description 26
- 230000001681 protective effect Effects 0.000 description 17
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 16
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- -1 naked and cDNAs) Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001746 injection moulding Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 4
- 108010011459 Exenatide Proteins 0.000 description 4
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960001093 lixisenatide Drugs 0.000 description 2
- 108010004367 lixisenatide Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- MSFZPBXAGPYVFD-NFBCFJMWSA-N (2r)-2-amino-3-[1-[3-[2-[2-[2-[4-[[(5s)-5,6-diamino-6-oxohexyl]amino]butylamino]-2-oxoethoxy]ethoxy]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound NC(=O)[C@@H](N)CCCCNCCCCNC(=O)COCCOCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O MSFZPBXAGPYVFD-NFBCFJMWSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- URRAHSMDPCMOTH-LNLFQRSKSA-N Denagliptin Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229950010300 denagliptin Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940098262 kynamro Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 108091060283 mipomersen Proteins 0.000 description 1
- OSGPYAHSKOGBFY-KMHHXCEHSA-A mipomersen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@H]2C[C@@H]([C@H](O2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O OSGPYAHSKOGBFY-KMHHXCEHSA-A 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940036220 synvisc Drugs 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940007428 victoza Drugs 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Catching Or Destruction (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15170595.1 | 2015-06-03 | ||
| EP15170595 | 2015-06-03 | ||
| PCT/EP2016/062459 WO2016193353A1 (en) | 2015-06-03 | 2016-06-02 | Grasper for a needle sheath, cap, autoinjector and method of producing a grasper |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017146070A RU2017146070A (ru) | 2019-07-09 |
| RU2017146070A3 RU2017146070A3 (enExample) | 2019-11-07 |
| RU2720160C2 true RU2720160C2 (ru) | 2020-04-24 |
Family
ID=53365859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017146070A RU2720160C2 (ru) | 2015-06-03 | 2016-06-02 | Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11045610B2 (enExample) |
| EP (2) | EP4541395A3 (enExample) |
| JP (1) | JP6755891B2 (enExample) |
| KR (1) | KR102569868B1 (enExample) |
| CN (1) | CN107708770B (enExample) |
| AR (1) | AR104872A1 (enExample) |
| AU (1) | AU2016269705B2 (enExample) |
| BR (1) | BR112017025753B1 (enExample) |
| DK (1) | DK3302640T3 (enExample) |
| HK (1) | HK1249455A1 (enExample) |
| IL (1) | IL256006B (enExample) |
| MX (1) | MX2017015602A (enExample) |
| RU (1) | RU2720160C2 (enExample) |
| TW (1) | TW201707741A (enExample) |
| WO (1) | WO2016193353A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3458131T3 (da) | 2016-05-18 | 2022-05-23 | Sanofi Aventis Deutschland | Hylsterfjerner og fremgangsmåder til samling deraf |
| US10300214B2 (en) * | 2016-07-27 | 2019-05-28 | Shl Medical Ag | Cap assembly for a medicament delivery device |
| US10583255B2 (en) * | 2016-07-27 | 2020-03-10 | Shl Medical Ag | Medicament container assembly for a medicament delivery device |
| WO2018018167A1 (de) * | 2016-07-28 | 2018-02-01 | Tecpharma Licensing Ag | Injektionsvorrichtung mit äusserer kappe mit nadelschutzkappenentfernerelement und verfahren zum montieren einer injektionsvorrichtung |
| CH712753A2 (de) | 2016-07-28 | 2018-01-31 | Tecpharma Licensing Ag | Trennen einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Montieren einer Injektionsvorrichtung. |
| ES2870497T3 (es) * | 2017-06-02 | 2021-10-27 | Becton Dickinson France | Extractor de tapa de inyector médico |
| US10828425B2 (en) * | 2017-06-23 | 2020-11-10 | Shl Medical Ag | Needle shield remover and a medicament delivery device comprising the needle shield remover |
| EP3694586A1 (en) | 2017-10-12 | 2020-08-19 | Eli Lilly and Company | Needle shield puller for drug delivery system |
| DK3706841T3 (da) | 2017-11-07 | 2023-12-11 | Shl Medical Ag | Kanyleskjoldsfjerner og medikamentafgivelsesindretning, der omfatter kanyleskjoldsfjerneren |
| WO2019101613A1 (en) * | 2017-11-23 | 2019-05-31 | Sanofi | Apparatus for removing and retaining a needle shield |
| EP3574945B1 (en) * | 2018-05-31 | 2024-07-10 | Aspen Global Incorporated | Protective device comprising a protective cover with fixed claws |
| USD932006S1 (en) | 2018-11-21 | 2021-09-28 | Regeneron Pharmaceuticals, Inc. | Auto-injector cap |
| EP3666314A1 (en) * | 2018-12-10 | 2020-06-17 | Ares Trading S.A. | Injection device |
| AU2020228132B2 (en) * | 2019-02-26 | 2022-12-15 | Becton Dickinson France | Rigid needle shield remover with drop test feature for autoinjector |
| KR102607293B1 (ko) * | 2019-02-26 | 2023-11-29 | 벡톤 디킨슨 프랑스 | 자동 주사 장치용 강성 바늘 쉴드 분리기 |
| MX2021010055A (es) | 2019-02-26 | 2021-09-21 | Becton Dickinson France | Autoinyector con indicador de audio. |
| AU2020227209B2 (en) | 2019-02-26 | 2022-09-08 | Becton Dickinson France | Auto-injector with cap |
| CH714525A2 (de) * | 2019-03-28 | 2019-06-28 | Tecpharma Licensing Ag | Injektionsvorrichtung mit einer Kappe zur Entfernung einer Nadelschutzkappe von einem Produktbehälter und Verfahren zum Montieren einer Injektionsvorrichtung. |
| JP7608439B2 (ja) * | 2019-08-23 | 2025-01-06 | アムジエン・インコーポレーテツド | 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法 |
| FI4037735T3 (fi) | 2019-09-30 | 2025-11-25 | Amgen Inc | Lääkeaineen annostelulaite |
| CN114901330A (zh) | 2020-01-13 | 2022-08-12 | 美国安进公司 | 针头护罩移除器、药物递送装置、以及相关方法 |
| US20230347071A1 (en) * | 2020-07-01 | 2023-11-02 | Sanofi | Needle Shield Removal Assembly, Method for Assembling Thereof and Drug Delivery Device |
| AU2022369296A1 (en) | 2021-10-20 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating prurigo nodularis by administering an il-4r antagonist |
| GB2613642A (en) * | 2021-12-13 | 2023-06-14 | Owen Mumford Ltd | A needle shield remover |
| AU2022425608A1 (en) | 2021-12-30 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| CA3250514A1 (en) | 2022-05-02 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES |
| JP2025520434A (ja) | 2022-06-15 | 2025-07-03 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体Ｃ１ｓ抗体製剤 |
| WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
| MA71395A (fr) | 2022-07-08 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r |
| WO2024094698A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Front sub-assembly for a drug delivery device |
| WO2024094704A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Arrangement for a drug delivery device, drug delivery device and method for assembly |
| EP4611855A1 (en) | 2022-10-31 | 2025-09-10 | Sanofi | Audible indicator, indicator holder and method of assembling an audible indicator |
| EP4611848A1 (en) | 2022-10-31 | 2025-09-10 | Sanofi | Device body for a drug delivery device, assembly for a drug delivery device and drug delivery device |
| CN120187475A (zh) | 2022-10-31 | 2025-06-20 | 赛诺菲 | 用于药物递送装置的组件 |
| CN120129549A (zh) | 2022-10-31 | 2025-06-10 | 赛诺菲 | 具有两部分式用户指示符的药物递送装置 |
| EP4611849A1 (en) | 2022-10-31 | 2025-09-10 | Sanofi | Method for assembling an assembly for a drug delivery device and drug delivery device |
| WO2024094699A1 (en) | 2022-10-31 | 2024-05-10 | Sanofi | Container holder and drug delivery device comprising the container holder |
| EP4611851A1 (en) | 2022-10-31 | 2025-09-10 | Sanofi | Drug delivery device with feedback element and method for providing a user of a drug delivery device feedback regarding a dose dispensing process |
| EP4611846A1 (en) | 2022-10-31 | 2025-09-10 | Sanofi | Plunger for expelling a drug, drug delivery device, rear sub-assembly and corresponding methods |
| WO2024097714A1 (en) | 2022-11-01 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
| WO2024112935A1 (en) | 2022-11-23 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for improving bone growth by administering an il-4r antagonist |
| TW202502819A (zh) | 2023-03-22 | 2025-01-16 | 法商賽諾菲生物技術公司 | 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法 |
| TW202502820A (zh) | 2023-03-27 | 2025-01-16 | 美商再生元醫藥公司 | 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法 |
| KR20260010767A (ko) | 2023-04-14 | 2026-01-21 | 키맵 리미티드 | 항-ox40l 항체를 함유하는 약학적 제형 |
| WO2025059635A1 (en) | 2023-09-15 | 2025-03-20 | Genzyme Corporation | Treatment of hemophilia a with fitusiran |
| WO2025162928A1 (en) | 2024-01-29 | 2025-08-07 | Sanofi | Needle shroud unlock device for a medicament delivery device |
| WO2025162927A1 (en) | 2024-01-29 | 2025-08-07 | Sanofi | Purifying device, system and method for purifying a needle for delivering a medicament |
| WO2025162926A1 (en) | 2024-01-29 | 2025-08-07 | Sanofi | Needle arrangement, drug delivery device comprising the needle arrangement and method for operating the drug delivery device |
| WO2025171279A1 (en) | 2024-02-09 | 2025-08-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
| TW202547528A (zh) | 2024-04-01 | 2025-12-16 | 美商健臻公司 | 以非妥西蘭治療因子x缺失 |
| US20250388685A1 (en) | 2024-04-15 | 2025-12-25 | Sanofi Biotechnology | Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist |
| US20260070995A1 (en) | 2024-09-09 | 2026-03-12 | Marcella Ruddy | Methods for treating bullous pemphigoid by administering an il-4r antagonist |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070112310A1 (en) * | 2003-07-31 | 2007-05-17 | Sid Technologies Llc | Injecting apparatus |
| WO2009081103A1 (en) * | 2007-12-20 | 2009-07-02 | Ucb Pharma S.A. | Auto- injector with a syringe lock for locking the barrel coupling element and syringe coupled thereto in said retract position |
| RU2009102986A (ru) * | 2006-06-30 | 2010-08-10 | Эбботт Байотекнолоджи Лтд. (Bm) | Автоматическое инъекционное устройство |
| EP2361648A1 (en) * | 2010-02-18 | 2011-08-31 | Sanofi-Aventis Deutschland GmbH | Remover for a protective needle shield |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09285542A (ja) * | 1996-04-22 | 1997-11-04 | Takemasa Doumori | 注射針の誤剌防止用クリップ |
| GB2438590B (en) | 2006-06-01 | 2011-02-09 | Cilag Gmbh Int | Injection device |
| GB0625169D0 (en) | 2006-12-18 | 2007-01-24 | Medical House Plc The | Improved autoinjector |
| CN104324438B (zh) | 2008-01-11 | 2017-06-16 | Ucb医药有限公司 | 用于类风湿性关节炎患者的给药系统 |
| SI2326371T1 (sl) * | 2008-07-18 | 2019-12-31 | Ucb Biopharma Sprl | Sistem za dajanje zdravila za bolnike z revmatoidnim artritisom |
| CA2755779C (en) * | 2009-03-20 | 2015-11-10 | Antares Pharma, Inc. | Hazardous agent injection system |
| AR076466A1 (es) | 2010-04-27 | 2011-06-15 | Kelly Jose Luis | Sistema y proceso de potabilizacion de agua, a traves del medio ambiente y/o de agua obtenida de red municipal o colectiva, y/o de agua obtenida de pozo, y/o de agua obtenida en recipientes domesticos e industriales |
| US20120022937A1 (en) | 2010-07-22 | 2012-01-26 | Yahoo! Inc. | Advertisement brand engagement value |
| AU2012209222B2 (en) | 2011-01-24 | 2015-07-09 | Abbvie Biotechnology Ltd | Removal of needle shields from syringes and automatic injection devices |
| EP2489380A1 (en) | 2011-02-18 | 2012-08-22 | Sanofi-Aventis Deutschland GmbH | Injection device |
| EP2489383A1 (en) * | 2011-02-18 | 2012-08-22 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
| CN103814260A (zh) | 2011-06-22 | 2014-05-21 | 弗雷森纽斯医疗护理德国有限责任公司 | 零排放透析诊所 |
| JP2014533133A (ja) | 2011-10-07 | 2014-12-11 | ホーム・ダイアリシス・プラス・リミテッドＨｏｍｅ ＤｉａｌｙｓｉｓＰｌｕｓ， Ｌｔｄ． | 透析システムのための熱交換流体の精製 |
| CN103974734B (zh) | 2011-10-17 | 2016-11-09 | Shl集团有限责任公司 | 用于移除输送构件护罩的装置 |
| EP2583705A1 (en) | 2011-10-21 | 2013-04-24 | Sanofi-Aventis Deutschland GmbH | Indicator arrangement for an auto-injector |
| EP2596826A1 (en) * | 2011-11-24 | 2013-05-29 | Sanofi-Aventis Deutschland GmbH | Safety syringe |
| EP2596823A1 (en) * | 2011-11-24 | 2013-05-29 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
| EP2978478B1 (en) * | 2013-03-25 | 2021-05-26 | SHL Medical AG | Front cap for a medicament delivery device |
| EP2823836A1 (en) * | 2013-07-09 | 2015-01-14 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
| EP2823841A1 (en) | 2013-07-09 | 2015-01-14 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
| EP2823838A1 (en) * | 2013-07-09 | 2015-01-14 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
| WO2016132187A1 (en) | 2015-02-19 | 2016-08-25 | Renalyx Health Systems Pvt Ltd | A portable regenerative haemodialysis system and a method thereof |
-
2016
- 2016-06-01 TW TW105117157A patent/TW201707741A/zh unknown
- 2016-06-02 BR BR112017025753-0A patent/BR112017025753B1/pt active IP Right Grant
- 2016-06-02 EP EP24223535.6A patent/EP4541395A3/en active Pending
- 2016-06-02 DK DK16727462.0T patent/DK3302640T3/da active
- 2016-06-02 AR ARP160101626A patent/AR104872A1/es unknown
- 2016-06-02 KR KR1020177037817A patent/KR102569868B1/ko active Active
- 2016-06-02 HK HK18107996.9A patent/HK1249455A1/zh unknown
- 2016-06-02 JP JP2017562584A patent/JP6755891B2/ja active Active
- 2016-06-02 MX MX2017015602A patent/MX2017015602A/es unknown
- 2016-06-02 WO PCT/EP2016/062459 patent/WO2016193353A1/en not_active Ceased
- 2016-06-02 US US15/579,144 patent/US11045610B2/en active Active
- 2016-06-02 CN CN201680032188.5A patent/CN107708770B/zh active Active
- 2016-06-02 AU AU2016269705A patent/AU2016269705B2/en active Active
- 2016-06-02 EP EP16727462.0A patent/EP3302640B1/en active Active
- 2016-06-02 RU RU2017146070A patent/RU2720160C2/ru active
-
2017
- 2017-11-30 IL IL256006A patent/IL256006B/en unknown
-
2021
- 2021-06-11 US US17/345,720 patent/US12357770B2/en active Active
-
2025
- 2025-01-14 US US19/020,052 patent/US20250152839A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070112310A1 (en) * | 2003-07-31 | 2007-05-17 | Sid Technologies Llc | Injecting apparatus |
| RU2009102986A (ru) * | 2006-06-30 | 2010-08-10 | Эбботт Байотекнолоджи Лтд. (Bm) | Автоматическое инъекционное устройство |
| WO2009081103A1 (en) * | 2007-12-20 | 2009-07-02 | Ucb Pharma S.A. | Auto- injector with a syringe lock for locking the barrel coupling element and syringe coupled thereto in said retract position |
| EP2361648A1 (en) * | 2010-02-18 | 2011-08-31 | Sanofi-Aventis Deutschland GmbH | Remover for a protective needle shield |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4541395A3 (en) | 2025-05-14 |
| CN107708770A (zh) | 2018-02-16 |
| US20180133407A1 (en) | 2018-05-17 |
| US20210338940A1 (en) | 2021-11-04 |
| EP3302640A1 (en) | 2018-04-11 |
| BR112017025753B1 (pt) | 2022-11-22 |
| RU2017146070A (ru) | 2019-07-09 |
| AU2016269705A1 (en) | 2018-01-18 |
| EP4541395A2 (en) | 2025-04-23 |
| CN107708770B (zh) | 2021-02-26 |
| IL256006A (en) | 2018-01-31 |
| KR102569868B1 (ko) | 2023-08-24 |
| JP2018520738A (ja) | 2018-08-02 |
| HK1249455A1 (zh) | 2018-11-02 |
| EP3302640B1 (en) | 2025-02-12 |
| US12357770B2 (en) | 2025-07-15 |
| WO2016193353A1 (en) | 2016-12-08 |
| BR112017025753A2 (pt) | 2018-08-14 |
| IL256006B (en) | 2021-12-01 |
| DK3302640T3 (da) | 2025-05-05 |
| US20250152839A1 (en) | 2025-05-15 |
| RU2017146070A3 (enExample) | 2019-11-07 |
| JP6755891B2 (ja) | 2020-09-16 |
| AU2016269705B2 (en) | 2020-10-22 |
| KR20180015677A (ko) | 2018-02-13 |
| MX2017015602A (es) | 2018-04-30 |
| AR104872A1 (es) | 2017-08-23 |
| TW201707741A (zh) | 2017-03-01 |
| US11045610B2 (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2720160C2 (ru) | Зажим для колпачка для иглы, крышка, автоматическое инъекционное устройство и способ изготовления зажима | |
| RU2720168C2 (ru) | Держатель шприца и автоматическое инъекционное устройство | |
| RU2719957C2 (ru) | Фиксатор кожуха | |
| RU2719022C2 (ru) | Шприцедержатель для автоматического инъекционного устройства и способ его сборки | |
| RU2719917C2 (ru) | Устройство доставки лекарственного средства | |
| CN107750175B (zh) | 药物输送装置 | |
| CN111315429B (zh) | 柱塞和药物输送装置 | |
| TW201705994A (zh) | 自動注射器及組裝方法 | |
| CN107735125B (zh) | 易于刺穿药筒的药物输送装置 | |
| TW201729859A (zh) | 用於注射裝置之帽蓋 | |
| CN108601902B (zh) | 具有帽的药物输送装置 | |
| CN108495678A (zh) | 注射装置 | |
| CN109641109B (zh) | 听觉指示器 | |
| CN114602007A (zh) | 注射器支架和自动注射器 | |
| CN108367124A (zh) | 注射装置 | |
| CN108290011A (zh) | 具有针护罩移除机构的注射装置 | |
| CN107750176A (zh) | 用于覆盖针罩的盖组件以及用于装配盖组件的方法 | |
| EP3484556B1 (en) | Drug delivery device with controlled needle shield and cover sleeve | |
| CN108495674A (zh) | 注射装置 | |
| HK40001471A (en) | Drug delivery device with controlled needle shield and cover sleeve | |
| HK40001471B (en) | Drug delivery device with controlled needle shield and cover sleeve |